BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 5, 2026
Home » Blogs » BioWorld MedTech Perspectives » Forget the naysayers: interventional cardiology's outlook is great

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology / Imaging / Cardiovascular / CMS / FDA / Medicare

Forget the naysayers: interventional cardiology's outlook is great

May 5, 2011
By Mark McCarty

Top 10 reasons interventional cardiologists should be happy

By MARK McCARTY

Medical Device Daily Washington Editor

Dear Interventional Cardiologist,

Worried about Medicare reimbursement for the Next Great Stent? Concerned that FDA's massive regulatory girth will squash your drug-eluting balloon groove? Not to worry. Here are the top 10 reasons you should be thrilled with your choice of specialty.

Number 10: PCI numbers are flat of late, but just watch that Baby Boom fill your waiting room in the years to come.

Number 9: The transradial (through the wrist) route is gaining acceptance as an approach to coronary intervention.

Number 8: Americans aren't getting any skinnier!

Number 7: The latest hospital in-patient payment system proposed by the Centers for Medicare & Medicaid Services would slightly increase payment for PCI procedures in fiscal 2012.

Number 6: Abbott (Abbott Park, Illinois) recently won a CE mark for its bioresorbable stent, the BVS. Can FDA really afford to be more than two years behind? I don't think so!

Number 5: Someday – probably in the not-too-distant future – really rich dog owners will decide their mutts deserve the best, too.

Number 4: Intravascular ultrasound.

Number 3: The American Heart Association just came up with a list of nearly two dozen catheter-based treatments that should be considered for pediatric heart disease.

Number 2: Percutaneous delivery of heart valves, and ...

The Number 1 reason interventional cardiologists should be happy with their choice of specialty: Who in their right mind really wants to have their chest cracked open?

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2026.
  • Pancreas 3D hologram

    ASCO 2026: A revolution in pancreatic cancer

    BioWorld
    At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 2, 2026
  • Liver over digital lens background

    EASL 2026: Emerging liver disease targets to watch

    BioWorld
    At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

    BioWorld
    Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing